Rabbit Polyclonal KCNH1 Antibody

+ +

•  

   
     All lanes : Anti-KCNH1 Antibody (C-Term) at 1:2000 dilution Lane 1: COLO 205 whole cell lysate Lane 2: Human brain lysate Lane 3: Hela whole cell lysate Lane 4: MCF-7 whole cell lysate Lane 5: SH-SY5Y whole cell lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG,  (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 111 kDa Blocking/Dilution buffer: 5% NFDM/TBST.    

•  

   
     Immunofluorescent analysis of 4% paraformaldehyde-fixed,  0. 1% Triton X-100 permeabilized Hela cells labeling KCNH1 with P34534 at 1/25 dilution, followed by Dylight® 488-conjugated goat anti-Rabbit IgG secondary antibody at 1/200 dilution (green). Immunofluorescence image showing  Nucleus and Cytoplasm staining on Hela cell line.  Cytoplasmic actin is detected with Dylight® 554 Phalloidin(red). The nuclear counter stain is DAPI (blue).    

•  

   
     Overlay histogram showing Hela cells stained with P34534(green line).  The cells were fixed with 2% paraformaldehyde (10 min) and then permeabilized with 90% methanol for 10 min.  The cells were then icubated in 2% bovine serum albumin to block non-specific protein-protein interactions followed by the antibody (P34534,  1:25 dilution) for 60 min at 37ºC.  The secondary antibody used was Goat-Anti-Rabbit IgG, DyLight® 488 Conjugated Highly Cross-Adsorbed(OE188374) at 1/200 dilution for 40 min at 37ºC.  Isotype control antibody (blue line) was rabbit IgG1 (1μg/1x10^6 cells) used under the same conditions.  Acquisition of >10, 000 events was performed.    

The KCNH1 antibody targets the potassium voltage-gated channel subfamily H member 1 (KCNH1), a protein encoded by the KCNH1 gene. This gene belongs to the Ether-à-go-go (EAG) family of voltage-gated potassium channels, which regulate cellular excitability and proliferation. KCNH1. also known as Kv10.1. is primarily expressed in the central nervous system and plays a role in neuronal signaling, synaptic plasticity, and cell cycle control. Dysregulation of KCNH1 has been implicated in neurodevelopmental disorders, such as Temple-Baraitser syndrome and Zimmermann-Laband syndrome, often linked to gain-of-function mutations. Additionally, aberrant KCNH1 expression is observed in certain cancers, where it promotes tumor growth and metastasis.

KCNH1 antibodies are essential tools for studying the protein’s expression, localization, and function in physiological and pathological contexts. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to assess KCNH1 levels in tissues or cultured cells. Researchers also employ these antibodies to investigate channel dynamics, post-translational modifications, and interactions with regulatory proteins. Specificity and validation (e.g., via knockout controls) are critical due to potential cross-reactivity with related EAG family members. Commercial KCNH1 antibodies are typically raised against epitopes in the cytoplasmic C-terminal domain, which contains key regulatory regions. Understanding KCNH1’s role through antibody-based research may inform therapeutic strategies for neurological disorders and cancers linked to its dysfunction.